Navigation Links
ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients
Date:10/22/2007

WASHINGTON, Oct. 22 /PRNewswire-USNewswire/ -- Today, the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO) have released an updated joint guideline on the use of erythropoiesis-stimulating agents (ESAs), a class of drugs that stimulate the bone marrow to produce more red blood cells, to treat chemotherapy-related anemia.

"One goal of these guidelines is to inform clinicians with the most up-to-date evidence from high-quality studies regarding the risks and benefits of ESAs in patients with cancer," said J. Douglas Rizzo, MD, MS, co-chair of the guideline panel and Associate Professor of Medicine, Medical College of Wisconsin.

This updated guideline, originally published in 2002, was derived from systematic reviews and analysis of published clinical trials. It outlines the clotting risks of ESAs, makes recommendations on usage, and provides insights on disease progression and patient survival.

Specifically, the guideline:

-- Declares epoetin and darbepoetin equally safe and effective.

-- Recommends the use of ESAs as a treatment option for cancer patients

who become anemic as a result of chemotherapy when their hemoglobin

approaches or falls below 10 g/dL, as well as for patients with low-

risk myelodysplasia.

-- Suggests that when using ESAs, hemoglobin can be raised to (or near)

a concentration of 12 g/dL at which point the dosage should be

titrated to maintain that level. Dose reductions are also recommended

when hemoglobin rise exceeds 1 g/dL in any two-week period or when

the hemoglobin level exceeds 11 g/dL.

-- Recommends discontinuing use of ESAs beyond six to eight weeks if a

patient has not responded to the drug.

-- Recommends monitoring the iron levels of patients being treated with

ESAs and providing supplements accordingly.

-- Cautions against using ESAs for cancer patients not receiving

chemotherapy since recent trials have shown increased thromboembolic

risks and decreased survival under these circumstances.

"As new data become available, it is important to update clinical practice guidelines to ensure that physicians make treatment decisions based upon the most up-to-date available evidence," said Alan E. Lichtin, MD, guideline panel co-chair and Associate Professor of Medicine at the Cleveland Clinic Lerner College of Medicine in Cleveland, Ohio. "However, new evidence can also reinforce previous recommendations, as it did in this guideline."

ESAs carry an increased risk for blood clots, strokes, and heart attacks in some patients under certain conditions, spurring the FDA to call for new drug warning labels this past March. Following the FDA's warning, the Centers for Medicare & Medicaid Services (CMS) issued a National Coverage Decision this summer, outlining the specific conditions under which use of ESAs would be reimbursed for cancer patients.

"We hope that these evidence-based recommendations will influence practice standards and result in better care for patients," said Samuel Silver, MD, ASH Executive Committee Councillor, Chair, ASH Subcommittee on Reimbursement, and Professor of Internal Medicine at the University of Michigan in Ann Arbor, Michigan.

In developing the guideline update, panel members considered two meta-analyses that reviewed close to 60 randomized clinical trials. Additional evidence was considered when it was considered pertinent to each section of the updated guideline.

The guideline is published ahead of print on the Web sites of Blood, ASH's scientific journal (http://bloodjournal.hematologylibrary.org/cgi/content/abstract/blood-2007- 08-109488v1), and ASCO's Journal of Clinical Oncology (http://www.jco.org). The guideline will be published in print in both journals on December 1.

The American Society of Hematology (http://www.hematology.org) is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology. Blood, the official journal of the American Society of Hematology, is the most cited peer-reviewed publication in the field. Blood is issued to Society members and other subscribers twice per month, available in print and online at http://www.bloodjournal.org.

The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians of all oncology subspecialties who care for people with cancer. ASCO's nearly 25,000 members from the United States and abroad set the standard for patient care and lead the efforts to discover more effective cancer treatments, increase funding for clinical and translational research, and, ultimately, improve cancer care for the estimated 10 million people diagnosed with cancer worldwide each year. ASCO publishes the Journal of Clinical Oncology (JCO), the preeminent, peer-reviewed, medical journal on clinical cancer research, and produces People Living With Cancer (http://www.PLWC.org), a comprehensive consumer Web site providing oncologist-vetted cancer information to help patients and families make informed health-care decisions.


'/>"/>
SOURCE American Society of Hematology
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
2. Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
3. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
4. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
5. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
6. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
7. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
8. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
9. OREXIGEN Therapeutics Announces Sustained-Release Formulation of Zonisamide Shows Improved Tolerability When Compared to Immediate Release Formulation
10. New Research Confirms the Benefit of Extended-Release Dipyridamole Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk Patients
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
Breaking Medicine News(10 mins):